Cancer Letters
Volume 225, Issue 1 , Pages 61-74 , 8 July 2005

Interferon-alpha promotes the anti-proliferative effect of Erlotinib (OSI-774) on human colon cancer cell lines

  • Jia-Lin Yang

      Affiliations

    • Department of Surgery and Surgical Oncology Research Group, Prince of Wales Clinical School, University of New South Wales, Barker Street, Randwick, Sydney, NSW 2031, Sydney, Australia
    • Corresponding Author InformationCorresponding author. Tel.: +61 2 93822624; fax: +61 2 93822629.
    • ,
  • Xian-Jun Qu

      Affiliations

    • Department of Pharmacology, College of Pharmacy, Shandong University, Jinan, People's Republic of China
    • ,
  • Pamela J. Russell

      Affiliations

    • Oncology Research Centre, Prince of Wales Hospital, University of New South Wales, Sydney, Australia
    • ,
  • David Goldstein

      Affiliations

    • Department of Medical Oncology, Prince of Wales Hospital, University of New South Wales, Sydney, Australia

Received 20 August 2004 ,Revised 20 November 2004 ,Accepted 24 November 2004.

References 

  1. Elledge RM, Fuqua SAW. Estrogen and progesterone receptors. In:  Harris JR,  Lippman ME,  Morrow M editor. Osborne, Diseases of the Breast. second ed. Philadelphia: Lippincott, Williams and Wilkins; 2000;p. 471
  2. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, et al. Pathological findings from the national surgical adjuvant breast and bowel project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J. Clin. Oncol. 1990;8:103–112
  3. Supramanian R, Smith DP, Coates MS. Survival from Cancer in New South Wales in 1980–1995. Sydney: NSW Cancer council; 1998;
  4. Wells A. Molecules in focus, EGFR receptor. Int. J. Biochem. Cell Biol. 1999;31:637–643
  5. Perry JE, Grossman ME, Tindall DJ. Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line. Prostate. 1998;35:117–124
  6. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther. 1999;82:241–250
  7. Grunwald V, Hidlago M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J. Natl Cancer Inst. 2003;95:851–867
  8. Ge H, Gong X, Tang CK. Evidence of high incidence of EGFR VIII expression and coexpression with EGFR in human invasive breast cancer by laser capture micro-dissection and immunohistochemical analysis. Int. J. Cancer. 2002;98:357–361
  9. Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, et al. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl Cancer Inst. 1998;90:824–832
  10. Blackledge G, Averbuch S. Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors. Br. J. Cancer. 2004;90:566–572
  11. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2003;21:2237–2246
  12. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. J. Am. Med. Assoc. 2003;290:2149–2158
  13. Grunwald V, Hidalgo M. Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774). Adv. Exp. Med. Biol. 2003;532:235–246
  14. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol. 2004;22:77–85
  15. Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 2004;22:1201–1208
  16. Bos M, Medelsohn J, Kim YM, Albanell J, Fry DW, Baselga J. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin. Cancer Res. 1997;3:2099–2106
  17. Hambek M, Solbach C, Schuerch HG, Roller M, Stegmueller M, Sterner-Kock A, et al. Tumor necrosis factor α sensitizes low epidermal growth factor receptor-expressing carcinomas for anti-EGFR therapy. Cancer Res. 2001;61:1045–1049
  18. Grünwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J. Natl Cancer Inst. 2003;95:851–867
  19. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating Mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004;350:1–11
  20. Yang J-L, Qu X-J, Russell PJ, Goldstein D. Regulation of epidermal growth factor receptor in human colon cancer cell lines by interferon alpha. Gut. 2004;53:123–129
  21. Goldstein D, Bushmeyer SM, Witt PL, Jordan VC, Borden EC. Effects of type I and II interferons on cultured human breast cells: interaction with estrogen receptors and with tamoxifen. Cancer Res. 1989;49:2698–2702
  22. Robinson SP, Goldstein D, Witt PL, Borden EC, Jordan VC. Inhibition of hormone-dependent and independent breast cancer cell growth in vivo and in vitro with the antiestrogen toremifene and recombinant human interferon-alpha 2. Breast Cancer Res. Treat. 1990;5:95–101
  23. Yang J-L, Qu X-J, Russell PJ, Goldstein D. Interferon-alpha enhances the anti-proliferative effect of Erlotinib (OSI-774) on human colon cancer cell lines. Am. Assoc. Cancer Res. 2004;4650;(95th Annual Meeting)
  24. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res. 2001;7:1459–1465
  25. Chill JH, Nivasch R, Levy R, Alback S, Schreiber G, Anglister J. The human interferon receptor: NMR-based modelling, mapping of the IFN-alpha 2 binding site, and observed ligand-induced tightening. Biochemistry. 2002;41:3575–3585
  26. Leaman DW, Pisharody S, Flicking TW, Commane MA, Schlessinger J, Kerr IM, et al. Roles of JAKs in activation of STATs and stimulation of c-fos gene expression by epidermal growth factor. Mol. Cell Biol. 1996;16:369–375
  27. Rane SG, Reddy P. Janus kinases: components of multiple signaling pathways. Oncogene. 2000;19:5662–5679
  28. Fish EN, Ghislain J, Trogadis J, Stevens JK. Inhibitory effects of alpha-interferon on epidermal growth factor-mediated receptor-dependent events. Cancer Res. 1993;53:5148–5157
  29. Panaretakis T, Pokrovskaja K, Shoshan MC, Grander D. Interferon-α induced apoptosis in U266 cells is associated with activation of the proapoptotic Bcl-2 family members Bak and Bax. Oncogene. 2003;22:4543–4556
  30. She QB, Solit D, Basso A, Moasser M. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akr pathway signaling. Clin. Cancer Res. 2003;9:4340–4346
  31. Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen M, et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene. 2003;22:2812–2822
  32. Chou T-C, Talalay P. Quantitative analysis of dose–effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984;22:27–55

PII: S0304-3835(04)00936-X

doi: 10.1016/j.canlet.2004.11.041

Cancer Letters
Volume 225, Issue 1 , Pages 61-74 , 8 July 2005

Article Tools

* Image Usage & Resolution